| Literature DB >> 31738894 |
Inge E Krabbendam1, Birgit Honrath2, Laura Bothof2, Eduardo Silva-Pavez3, Hernán Huerta3, Natalia M Peñaranda Fajardo4, Frank Dekker5, Martina Schmidt2, Carsten Culmsee6, Julio César Cárdenas7, Frank Kruyt4, Amalia M Dolga8.
Abstract
Brain tumours are among the deadliest tumours being highly resistant to currently available therapies. The proliferative behaviour of gliomas is strongly influenced by ion channel activity. Small-conductance calcium-activated potassium (SK/KCa) channels are a family of ion channels that are associated with cell proliferation and cell survival. A combined treatment of classical anti-cancer agents and pharmacological SK channel modulators has not been addressed yet. We used the gold-derivative auranofin to induce cancer cell death by targeting thioredoxin reductases in combination with CyPPA to activate SK channels in neuro- and glioblastoma cells. Combined treatment with auranofin and CyPPA induced massive mitochondrial damage and potentiated auranofin-induced toxicity in neuroblastoma cells in vitro. In particular, mitochondrial integrity, respiration and associated energy generation were impaired. These findings were recapitulated in patient-derived glioblastoma neurospheres yet not observed in non-cancerous HT22 cells. Taken together, integrating auranofin and SK channel openers to affect mitochondrial health was identified as a promising strategy to increase the effectiveness of anti-cancer agents and potentially overcome resistance.Entities:
Year: 2019 PMID: 31738894 DOI: 10.1016/j.bcp.2019.113714
Source DB: PubMed Journal: Biochem Pharmacol ISSN: 0006-2952 Impact factor: 5.858